Successful treatment of oral potentially malignant lesions with ruxolitinib in STAT3 gain-of-function disease

Oral Oncol. 2022 Sep:132:106015. doi: 10.1016/j.oraloncology.2022.106015. Epub 2022 Jul 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Gain of Function Mutation*
  • Humans
  • Nitriles
  • Pyrazoles* / therapeutic use
  • Pyrimidines
  • STAT3 Transcription Factor

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • ruxolitinib